title: [Preclinical hereditary hemochromatosis--is there an indication for preventive screening?].
abstract: A 54 year-old previously healthy woman was admitted with staphylococcus aureus septicaemia. The patient had been treated with oral iron supplementation for two years due to fatigue. In the evaluation of postinfectious anaemia, serum transferrin saturation and serum ferritin were found persistently elevated with values of 74% and 950 micrograms/1, respectively. Hereditary haemochromatosis was suspected even though there was no history of liver disease or diabetes mellitus in the family. A bone marrow biopsy showed a normal content of haemosiderin iron. The liver biopsy revealed haemosiderosis, mainly located to the periportal hepatocytes, and fibrosis in the portal tracts. The HLA-type was A3, B7, B37. Over a period of ten months, a total of 3.9 g of iron was removed by venesection while S-ferritin declined to 31 micrograms/l. A sister to the proband had an identical HLA type, but normal iron status markers, either indicating heterozygosity or homozygosity with lack of penetrance. In preclinical hereditary haemochromatosis, early diagnosis and treatment is essential in order to prevent organ damage and to improve prognosis. Prophylactic screening is recommended. The identification of one homozygous subject in a Danish year-cohort of 60.000 persons costs approximately 40.000 Danish kroner (7.000 US+).
authors.affiliation: Klinisk-biokemisk afdeling, medicinsk-lungemedicinsk afdeling Y, Amtssygehuset i Gentofte.
authors.forename: K E
authors.initials: KE
authors.lastname: Grønbaek
authors.forename: N
authors.initials: N
authors.lastname: Milman
authors.forename: V
authors.initials: V
authors.lastname: Skødt
mesh_terms: D003718:Denmark; D003937:Diagnosis, Differential; D005260:Female; D006432:Hemochromatosis / Q000175:diagnosis / Q000235:genetics / Q000517:prevention & control*; D006801:Humans; D008403:Mass Screening / Q000191:economics; D008875:Middle Aged; D011379:Prognosis
vernacular_title: Praeklinisk hereditaer haemokromatose--er der behov for profylaktisk screening?